AJP Asia Intelligence Agency

Aribio Lab Shares Surge After Alzheimer’s Drug Delays Symptoms by 31%

Aribio's oral Alzheimer’s treatment candidate has reportedly delayed the clinical deterioration rate by 31% in a patient group that did not take existing symptom-relief medications, leading to a surge in the stock price of related listed company Aribio Lab, which reached its price limit.


According to the Korea Exchange on November 18, as of 1:36 PM, Aribio Lab's shares were trading at 5,290 won (KRW), up 1,220 won (29.98%) from the previous trading day. The stock opened at 4,785 won (KRW) and expanded its gains throughout the day to hit the upper limit.


The rise in stock price was driven by the announcement related to the global Phase 3 clinical trial of the oral Alzheimer’s treatment candidate. Aribio confirmed the results the previous day, stating that the candidate delayed clinical deterioration by 31% in a patient group that did not take existing symptom-relief medications. Aribio, the drug developer, is a non-listed company traded on K-OTC and is a separate entity from Aribio Lab.


The clinical trial was designed to analyze 604 participants who did not take existing symptom-relief medications such as acetylcholinesterase inhibitors or memantine, comparing the 'monotherapy group' with all clinical participants. This design followed consultations with major regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Jae-jun Jeong, CEO of Aribio, stated, "The 31% delay in clinical deterioration confirmed at the one-year mark in the monotherapy group supports our hypothesis," adding, "We aim to quickly enter the FDA approval application process based on these global clinical trial results." Aribio plans to apply for FDA approval next year and aims for commercialization in 2028.





* This article has been translated by AI.